SINOVAC-Sponsored Automated Complex for Vaccine Storage and Distribution is Delivered to the Egyptian
2022-10-21

On September 24, the handover ceremony of the Chinese government's donation of COVID-19 vaccine to Egyptian women, children, and adolescents & the delivery ceremony of SINOVAC's sponsored automated complex for vaccine storage were held at VACSERA, the Egyptian biological products and vaccine company.

The 10 million doses of SINOVAC COVID-19 vaccine, CoronaVac, provided by the Chinese government through the organization of African First Ladies are the first batch of vaccines to be stored and transported after the cold storage is completed. These vaccines are specifically to help Egyptian women, children, and adolescents fight against the COVID-19 and strengthen the anti-epidemic capabilities of African women and children.

The automatic complex was built on an area of 2800 square meters, storing up to 150 million doses of vaccines. It can realize automatic management loading and unloading dispatch. Improving the storage system's operation efficiency can also reduce the operating cost of cold storage and ensure vaccine storage safety.

The cold storage facility built by SINOVAC this time is the one with the largest storage capacity and the highest degree of automation of its kind in Africa, said Zhang Tao, the Charge d’affaires of the Chinese embassy in Egypt.  

"It means a lot to have a project like that in Egypt ," Egyptian Minister of Health and Population Mr. Khaled Abdel-Ghaffar said . " We can see it now when we go inside, you see how an automated logistic center like that would be for the future of this critical industry."

About SINOVAC

Sinovac Biotech Ltd., (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.

SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A and B, seasonal influenza, pneumococcal disease, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella, mumps, and poliomyelitis.

The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The Healive®, hepatitis A vaccine, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine commercialized in China in 2016. In 2022, SINOVAC’s Sabin-strain inactivated polio vaccine (sIPV) was prequalified by the WHO.

SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.

SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.

For more information, please see the Company’s website at www.sinovac.com.

 

Contact:

Sinovac Biotech Ltd.

PR Team

pr@sinovac.com


© SINOVAC